Last updated: 2026-09-06 06:38:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Voyager Therapeutics, Inc. (VYGR) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $3.51, with a market capitalisation of $218.13M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.94 to $5.55. This page covers its latest market performance, valuation, price trends and company information.
$218.13M | |
$3.34 | |
$31.91 | |
$2.46 | |
$3.38 | |
367.39K | |
-- | |
-- | |
$5.55 | |
$2.94 | |
-- | |
-- |
Voyager Therapeutics, Inc. (VYGR) last closed at $3.38 as of 2026-09-04 23:31:00, unchanged from the previous close of $3.38.
During the latest regular trading session, VYGR traded between $2.46 and $31.91, with a volume of 367.39K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Voyager Therapeutics, Inc. (VYGR) moved from $3.51 to $3.51, representing a gain of 0.06% ($0.00).
The stock traded between $3.34 and $3.51 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 426.81 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 22.1%
VYGR is currently trading at $3.51, placing it 22.1% of the way from its 52-week low of $2.94 to its 52-week high of $5.55. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 141 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Voyager Therapeutics, Inc. (VYGR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.